CLINICAL TRIAL / NCT05548296

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

  • Interventional
  • Recruiting
  • NCT05548296

Contact Information

  • Bailey Wedig

A Phase 2 Study of ACR-368 Therapy in Subjects With Endometrial Cancer

This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.